Work

A multicenter, randomized phase II study of rilotumumab (R) (AMG 102) or placebo (Pbo) plus mitoxantrone (M) and prednisone (P) in patients (pts) with previously treated castrate-resistant prostate cancer (CRPC).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.5_suppl.115

Authors: Charles J. Ryan, Mark Rosenthal, Siobhan Ng, Joshi J. Alumkal, Joel Picus, Gwenaelle Gravis, Karim Fizazi, Frederic Forget, Jean-Pascal H. Machiels, Min Zhu, Joe Jiang, Sarita Dubey, Elwyn Loh, Winald R. Gerritsen

Institutions: Université Paris-Sud, The Royal Melbourne Hospital, Inserm, Oregon Health & Science University, University of California, San Francisco, Institut Gustave Roussy, Institut Paoli-Calmettes

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2243976512

Cites:

Cited by: 8

Related to: 10